Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.45 |
| ▸ | MELK | Q14680 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 2/20 | 0.42 |
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | HRH2 | P25021 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5166411 | 0.84 | GRM2 (0.56) | HDAC1HRH3LTA4HGRM2MAP4K4 | |
| SCHEMBL5166151 | 0.84 | HDAC1 (0.49) | HDAC1HRH3LTA4HGRM2JAK2 | |
| SCHEMBL13771990 | 0.83 | MAP4K4 (0.42) | HDAC1HRH3LTA4HGRM2MAP4K4 | |
| SCHEMBL5165935 | 0.82 | HDAC1 (0.63) | HDAC1HRH3LTA4HJAK2CHRM4 | |
| SCHEMBL5165601 | 0.81 | HDAC1 (0.56) | HDAC1HRH3LTA4HGRM2MELK | |
| SCHEMBL5164995 | 0.81 | HDAC1 (0.53) | HDAC1HRH3LTA4HGRM2JAK2 | |
| SCHEMBL5191116 | 0.80 | LSS (0.52) | HDAC1HRH3LTA4HGRM2MAP4K4 | |
| SCHEMBL5188483 | 0.80 | LSS (0.52) | HDAC1HRH3LTA4HGRM2MAP4K4 | |
| SCHEMBL19496612 | 0.79 | HDAC1 (0.55) | HDAC1HRH3LTA4HGRM2JAK2 | |
| SCHEMBL5952015 | 0.79 | HDAC1 (0.57) | HDAC1HRH3LTA4HGRM2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014733-A1 | Histamine-3 agonists and antagonists | PFIZER INC | 2006-01-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014733-A1 | Histamine-3 agonists and antagonists | HRH3, HRH4, HRH2 | HDAC1 1532/4885HRH3 1/4885LTA4H 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.